{"generic":"Diphtheria, Tetanus, Acellular Pertussis Vaccine","drugs":["Daptacel","Diphtheria, Tetanus, Acellular Pertussis Vaccine","Infanrix","Tripedia"],"mono":{"0":{"id":"924143-s-0","title":"Generic Names","mono":"Diphtheria, Tetanus, Acellular Pertussis Vaccine"},"1":{"id":"924143-s-1","title":"Dosing and Indications","sub":{"1":{"id":"924143-s-1-5","title":"Pediatric Dosing","mono":"<ul><li>use same brand of DTaP vaccine for all doses when feasible; for patients with a history of seizures, administer an appropriate antipyretic at time of vaccination and for 24 hours following<\/li><li><b>Vaccination for diphtheria, pertussis, and tetanus:<\/b> (6 weeks to younger than 7 years) 0.5 mL IM x 5 doses at 2, 4, and 6 months of age, and boosters at 15 to 18 months and at 4 to 6 years; fourth dose may be given as early as age 12 months provided 6 months have elapsed since the third dose (guideline dose); 0.5 mL IM x 5 doses at 2, 4, and 6 months of age, and boosters at 15 to 20 months and at 4 to 6 years old (manufacturer dose)<\/li><li><b>Vaccination for diphtheria, pertussis, and tetanus:<\/b> (4 years or older) if fourth dose administered at 4 years or older, do not administer fifth dose<\/li><li><b>Vaccination for diphtheria, pertussis, and tetanus:<\/b> (booster) if 4 doses of Pentacel(R) have been administered, give Daptacel(R) 0.5 mL IM as the fifth dose<\/li><li><b>Vaccination for diphtheria, pertussis, and tetanus:<\/b> (Infanrix(R)) if vaccination series initiated with Pediarix(R), may complete series with Infanrix(R)<\/li><\/ul>"},"3":{"id":"924143-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><br\/>Vaccination for diphtheria, pertussis, and tetanus<br\/>"}}},"3":{"id":"924143-s-3","title":"Contraindications\/Warnings","sub":[{"id":"924143-s-3-9","title":"Contraindications","mono":"<ul><li>encephalopathy (eg, coma, decreased level of consciousness, prolonged seizure) not attributable to another identifiable cause within 7 days of previous pertussis-containing vaccine<\/li><li>hypersensitivity or serious allergic reaction (eg, anaphylaxis) to any vaccine component<\/li><li>progressive neurologic disorder (eg, infantile spasm, uncontrolled epilepsy, progressive encephalopathy); defer vaccination until neurologic status is clarified and stabilized<\/li><li>gelatin or thimerosal allergy; Tripedia(R) product contains 0.3 mcg mercury per dose and gelatin from the manufacturing process<\/li><\/ul>"},{"id":"924143-s-3-10","title":"Precautions","mono":"<ul><li>acute illness with or without fever, moderate or severe; defer vaccination unless the benefit of protection outweighs the risk of an adverse reaction<\/li><li>brachial neuritis with administration of tetanus toxoid-containing vaccination has been reported<\/li><li>central nervous system disorders; consider risk versus benefit<\/li><li>coagulation disorders, including thrombocytopenia, hemophilia, or concomitant anticoagulant therapy; risk of hemorrhage with intramuscular injections; evaluate benefit\/risk and use proper technique<\/li><li>collapse or shock-like state (hypotonic-hyporesponsive episode) within 48 hours of receipt of previous a pertussis-containing vaccine; carefully evaluate risk\/benefit prior to administration<\/li><li>convulsions with or without fever occurring within 3 days of receipt of a previous pertussis-containing vaccine; carefully evaluate risk\/benefit prior to administration<\/li><li>Guillain-Barre syndrome within 6 weeks of previous tetanus toxoid-containing vaccination; increased risk of recurrence; carefully evaluate risk\/benefit prior to administration<\/li><li>hypersensitivity reaction, arthus-type, after a previous tetanus-toxoid-containing vaccine; defer vaccination until at least 10 years since last tetanus-toxoid-containing vaccine<\/li><li>immunocompromised, including those treated with immunosuppressive therapies (irradiation, antimetabolites, alkylating agents, cytotoxic drugs, and corticosteroids (greater than physiologic doses); may reduce immune response<\/li><li>latex allergy; vial stopper of Tripedia(R) and tip cap of prefilled Infanrix(R) syringes may contain latex rubber<\/li><li>persistent, inconsolable crying lasting for 3 hours or more, occurring within 48 hours of receipt of a previous pertussis-containing vaccine; carefully evaluate risk\/benefit prior to administration<\/li><li>premature infants; apnea has been observed following intramuscular vaccination; consider medical status and risk\/benefits prior to administration<\/li><li>revaccination in patients with unknown vaccination history; after the fourth and fifth dose an increased rate of adverse events may occur; serologic testing may be indicated<\/li><li>seizure risk; an antipyretic medication, may given at the time of vaccination and for 24 hours postvaccination for patients at an increased risk for seizures to reduce the occurrence post-vaccination fever<\/li><li>syncope, which may be accompanied by transient neurological signs (ie, visual disturbance, paresthesia, tonic-clonic limb movements), may occur<\/li><li>temperature of 40.5 degrees C (105 degrees F) or greater within 48 hours of receipt of a previous pertussis-containing vaccine; carefully evaluate risk\/benefit prior to administration<\/li><li>report suspected adverse reactions to the Vaccine Adverse Effects Reporting System (VAERS) at 1-800-822-7967 or www.vaers.hhs.gov<\/li><\/ul>"},{"id":"924143-s-3-11","title":"Pregnancy Category","mono":"C (FDA)<br\/>"},{"id":"924143-s-3-12","title":"Breast Feeding","mono":"Micromedex: Infant risk cannot be ruled out.<br\/>"}]},"4":{"id":"924143-s-4","title":"Drug Interactions","sub":{"1":{"id":"924143-s-4-14","title":"Major","mono":"<ul>Cyclosporine (theoretical)<\/ul>"},"2":{"id":"924143-s-4-15","title":"Moderate","mono":"<ul><li>Chloramphenicol (probable)<\/li><li>Meningococcal Vaccine, Tetanus Toxoid Conjugate Quadrivalent (established)<\/li><\/ul>"}}},"5":{"id":"924143-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Dermatologic:<\/b>Injection site reaction (Infanrix(R), 10% to 53.3%; Daptacel(R), up to 61.5%)<\/li><li><b>Gastrointestinal:<\/b>Loss of appetite (Infanrix(R), 16% to 23.3%; Daptacel(R) 8.4% to 11.2%)<\/li><li><b>Neurologic:<\/b>Somnolence (Infanrix(R), 17% to 54%; Daptacel(R), 18.9% to 32.7%)<\/li><li><b>Psychiatric:<\/b>Irritability (Infanrix(R), 52.2% to 61.6%; Daptacel(R), 22.9% to 75.8%)<\/li><li><b>Other:<\/b>Fever (Infanrix(R), 19.8% to 30.2%; Daptacel(R), 4.6% to 23.6%)<\/li><\/ul><b>Serious<\/b><ul><li><b>Immunologic:<\/b>Anaphylaxis<\/li><li><b>Neurologic:<\/b>Afebrile seizure (Infanrix(R), 0.13 per 1000 doses)<\/li><li><b>Other:<\/b>Fever, 104 degrees F or higher rectal temperature (Infanrix(R), 0.36 per 1000 doses; Daptacel(R), 7.8% to 23.6%)<\/li><\/ul>"},"6":{"id":"924143-s-6","title":"Drug Name Info","sub":[{"id":"924143-s-6-17","title":"US Trade Names","mono":"<ul><li>Daptacel<\/li><li>Infanrix<\/li><li>Tripedia<\/li><\/ul>"},{"id":"924143-s-6-18","title":"Synonyms","mono":"<ul><li>DTaP - Diphtheria, Tetanus, and Acellular Pertussis Vaccine<\/li><li>DTaP Vaccine<\/li><li>Diphtheria, Tetanus, and Acellular Pertussis Vaccine<\/li><li>Diphtheria Toxoid, Adsorbed; Pertussis Vaccine, Acellular; and Tetanus Toxoid<\/li><\/ul>"},{"id":"924143-s-6-19","title":"Class","mono":"Vaccine<br\/>"},{"id":"924143-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"},{"id":"924143-s-6-21","title":"Generic Availability","mono":"No<br\/>"}]},"7":{"id":"924143-s-7","title":"Mechanism Of Action","mono":"<ul><li>Diphtheria toxoid component helps reduce the risk of developing diphtheria and induces the development of neutralizing antibodies to the diphtheria toxin. The vaccine protects immunized persons for at least 10 years and enables vaccine recipients to develop only a mild form of the disease in case they do develop diphtheria.<\/li><li>Tetanus toxoid component stimulates the development of neutralizing antibodies to tetanus toxin and protects adequately immunized persons against tetanus for at least 10 years.<\/li><li>Acellular pertussis vaccine component protects adequately immunized persons against Bordetella pertussis. The exact mechanism of action of immunity to pertussis is unknown.<\/li><\/ul>"},"9":{"id":"924143-s-9","title":"Administration","mono":"<ul><li><b>General Information<\/b><br\/>IM only; do not give subQ, IV, or intradermally<br\/><\/li><li><b>Intramuscular<\/b><br\/><ul><li>shake vial  or prefilled syringe  well<\/li><li>concomitant administration with other vaccines should be given with different syringes; do not mix Infanrix(R) with any other vaccine in the same syringe or vial<\/li><li>preferred injection site in infants younger than 1 year is the anterolateral aspect of the thigh; the deltoid muscle of the upper arm may be used in older children<\/li><li>do not inject into the gluteal area or areas where there is a major nerve trunk<\/li><li>consider using a 25-mm needle rather than a 16-mm needle to reduce occurrence of a local injection site reaction<\/li><\/ul><\/li><\/ul>"},"11":{"id":"924143-s-11","title":"How Supplied","mono":"<ul><li><b>Daptacel<\/b><br\/>Intramuscular Suspension: (Diphtheria Toxoid, Adsorbed - Pertussis Vaccine, Acellular - Tetanus Toxoid) 15 Lf U\/0.5 ML-23 MCG\/0.5 ML-5 Lf U\/0.5 ML<br\/><\/li><li><b>Infanrix<\/b><br\/>Intramuscular Suspension: (Diphtheria Toxoid, Adsorbed - Pertussis Vaccine, Acellular - Tetanus Toxoid) 25 Lf U\/0.5 ML-58 MCG\/0.5 ML-10 Lf U\/0.5 ML<br\/><\/li><\/ul>"},"13":{"id":"924143-s-13","title":"Clinical Teaching","mono":"<ul><li>Instruct caregiver to report any adverse reactions the child may have experienced within 48 h after receiving the vaccination, especially, temperature 40.5 degrees C (105 degrees F) or greater which is not attributable to any other cause, collapse or shock-like state, or persistent crying lasting 3 h or more.<\/li><li>Caregiver should also report if child experiences convulsions with or without fever within 3 days of receiving vaccine.<\/li><li>Inform caregiver of the importance of the child receiving the entire series of vaccinations in the absence of contraindications. If a dose is missed, another appointment should be scheduled as soon as possible.<\/li><\/ul>"}}}